logo
Plus   Neg
Share
Email

5 Top Losers In Healthcare Sector (PAHC, DVCR, XTNT…)

pharmadown aug28 lt

The following are some of the healthcare stocks that posted the biggest percentage decline on Wednesday.

1. Phibro Animal Health Corporation (PAHC)

Phibro Animal Health is a global diversified animal health and mineral nutrition company.

Lost 31.14% to close Wednesday's (Aug.28) trading at $21.74.

News: The Company reported disappointing results for its fourth quarter and fiscal year ended June 30, 2019, as the African swine fever resulted in lower domestic demand from the poultry and swine sectors.

Net sales for its fourth quarter ended June 30, 2019, were $204 million, a decrease of 4% over the comparable year-ago quarter. Net income for the recent fiscal fourth quarter was $9 million or $0.22 per share compared to $22.1 million or $0.55 per share in the year-ago quarter.

Looking ahead, the Company expects the effects of African swine fever to have an even larger impact in the new fiscal year.

2. Diversicare Healthcare Services Inc. (DVCR)

Diversicare is a premier provider of long-term care services.

Lost 14.93% to close Wednesday's trading at $1.71.

News: The trading of the Company's common stock will be suspended on the Nasdaq Stock Market at the opening of business on August 29, 2019, as its Market Value of Listed Securities ("MVLS") no longer meets the minimum MVLS of $35 million.

Following delisting, the shares will begin trading on the OTCQX at the opening of business on August 29, 2019.

3. Xtant Medical Holdings Inc. (XTNT)

Xtant Medical is a commercial-stage global medical technology company focused on surgical solutions for the treatment of spinal disorders.

Lost 11.68% to close Wednesday's trading at $2.53.

News: No news

Recent event:

On August 8, 2019, the Company reported financial results for the second quarter ended June 30, 2019.

Net loss for the second quarter of 2019 narrowed to $1.9 million or $0.15 per share from $5.0 million or $0.38 per share in the year-ago quarter. Revenue for the second quarter of 2019 was $15.3 million, compared to $18.7 million for the same prior-year period.

4. Salarius Pharmaceuticals Inc. (SLRX)

Salarius Pharma is a clinical-stage oncology company targeting the epigenetic causes of cancers.

Lost 11.28% to close Wednesday's trading at $9.60.

News: No news

Pipeline :

Seclidemstat is the lead drug candidate of Salarius and is currently being tested in a Phase 1 study for refractory or relapsed Ewing's sarcoma and a Phase 1 study for Advanced Solid Tumors.

Recent event:

-- On August 26, 2019, the Company entered into a collaborative partnership with the Ivy Brain Tumor Center at the Barrow Neurological Institute to test Seclidemstat for the treatment of glioblastoma.
-- On January 4, 2019, privately-held Salarius merged with public-listed Flex Pharma Inc., and the combined company was renamed Salarius Pharmaceuticals Inc.

5. Ra Medical Systems Inc. (RMED)

Ra Medical is a commercial-stage medical device company, with a focus on vascular and dermatological diseases.

Lost 9.09% to close Wednesday's trading at $1.50.

News: No news

Recent event:

On August 23, 2019, the Company received a notice from the NYSE indicating that it is not in compliance with the NYSE's continued listing requirements due to delay in Form 10-Q filing.

Ra Medical has six months from August 19, 2019, to file the Form 10-Q with the SEC.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT